Oxycodone/naloxone

Oxycodone/naloxone
Combination of
Oxycodone Opioid analgesic
Naloxone Opioid receptor antagonist
Clinical data
AHFS/Drugs.com International Drug Names
UK Drug Information
Pregnancy
category
  • C
Legal status
Routes of
administration		 Oral
Identifiers
ATC code N02AA55
  (verify)

The combination oxycodone is an opioid analgesic available as managed-release tablets under the trade names Targin (produced by Mundipharma), Targiniq and Targinact. Oxycodone is responsible for the pain-relieving effects, while naloxone - while not active if taken orally - will precipitate severe opiate withdrawal symptoms if the pill is crushed up and injected. Constipation was significantly relieved in a 2008 study.[1] The drug was released in 2006 in Germany and is available in some other European countries since 2009.[2]

Adverse effects

Further information: Oxycodone § Adverse effects

See also

References

  1. ↑ Simpson K, et al. (December 2008). "Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain". Curr Med Res Opin 24 (12): 3503–3512. doi:10.1185/03007990802584454. PMID 19032132. Retrieved 2009-04-09.
  2. ↑ Mundipharma (2009-01-26). "Targin (oral oxycodone/naloxone prolonged-release tablet) now launching across Europe to control severe chronic pain with significantly reduced risk of opioid-induced constipation". Retrieved 2009-04-09.



This article is issued from Wikipedia - version of the Wednesday, September 02, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.